Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Moreau

Showing results (191-200 of 787) with videos related to

Pageof 79
Sort By:
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
Blood|May 31, 2012
Proteasome inhibitors in multiple myeloma: 10 years laterPhilippe Moreau, Paul G Richardson, Michele Cavo, et al.
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
ACS Omega|April 20, 2026
Optimization of Hot Forging Process Parameters of Alloy CuZn40Pb2 Using an Experimental and Numerical ApproachSouhir Hammami, Philippe Moreau, José Gregorio La Barbera-Sosa, et al.
ACS Omega|August 29, 2019
Biochemical Characterization of the α-l-Rhamnosidase <i>Dt</i>Rha from <i>Dictyoglomus thermophilum</i>: Application to the Selective Derhamnosylation of Natural FlavonoidsLaure Guillotin, Hyuna Kim, Yasmina Traore, et al.
Haematologica|September 8, 2006
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapyRégis Bataille, Gaëtan Jégo, Nelly Robillard, et al.
British Journal of Haematology|October 14, 2023
Quad-class exposed/refractory myeloma is associated with short survivalBénédicte Piron, Domitille Costes-Tertrais, Thomas Gastinne, et al.
Leukemia & Lymphoma|November 5, 2013
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myelomaEric Jourdan, Veronique Leblond, Hervé Maisonneuve, et al.
ACS Applied Materials & Interfaces|March 14, 2023
Coordinatively Cross-Linked Binders for Silicon-Based Electrodes for Li-Ion Batteries: Beneficial Impact on Mechanical Properties and Electrochemical PerformanceLucas Huet, Driss Mazouzi, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie, Michel Attal, John Crowley, et al.
Pageof 79

Showing results (191-200 of 787) with videos related to

Sort By:
Pageof 79
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
Blood|May 31, 2012
Proteasome inhibitors in multiple myeloma: 10 years laterPhilippe Moreau, Paul G Richardson, Michele Cavo, et al.
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
ACS Omega|April 20, 2026
Optimization of Hot Forging Process Parameters of Alloy CuZn40Pb2 Using an Experimental and Numerical ApproachSouhir Hammami, Philippe Moreau, José Gregorio La Barbera-Sosa, et al.
ACS Omega|August 29, 2019
Biochemical Characterization of the α-l-Rhamnosidase <i>Dt</i>Rha from <i>Dictyoglomus thermophilum</i>: Application to the Selective Derhamnosylation of Natural FlavonoidsLaure Guillotin, Hyuna Kim, Yasmina Traore, et al.
Haematologica|September 8, 2006
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapyRégis Bataille, Gaëtan Jégo, Nelly Robillard, et al.
British Journal of Haematology|October 14, 2023
Quad-class exposed/refractory myeloma is associated with short survivalBénédicte Piron, Domitille Costes-Tertrais, Thomas Gastinne, et al.
Leukemia & Lymphoma|November 5, 2013
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myelomaEric Jourdan, Veronique Leblond, Hervé Maisonneuve, et al.
ACS Applied Materials & Interfaces|March 14, 2023
Coordinatively Cross-Linked Binders for Silicon-Based Electrodes for Li-Ion Batteries: Beneficial Impact on Mechanical Properties and Electrochemical PerformanceLucas Huet, Driss Mazouzi, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie, Michel Attal, John Crowley, et al.
Pageof 79